Bulletin
Investor Alert

Jan. 25, 2022, 6:53 a.m. EST

mRNA Vaccine And Therapeutics Market 2021-2026: Global Size, Share, Trends And Forecast

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    BioNTech SE ADR (BNTX)
  • X
    CRISPR Therapeutics AG (CRSP)

or Cancel Already have a watchlist? Log In

Jan 25, 2022 (SUPER MARKET RESEARCH via COMTEX) -- According to IMARC Group's latest report, titled " mRNA Vaccine and Therapeutics Market : Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026," the global mRNA vaccines and therapeutics market potential is expected to reach a value of US$ 9.41 Billion in 2021. Looking forward, the market is expected to register a CAGR of 10.5% during 2021-2026, reaching a value of US$ 15.49 Billion by 2026.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

The messenger ribonucleic acid, or mRNA, refers to a protein-coding gene in the genome that provides a basis for protein synthesis within the cells. The mRNA vaccines and therapeutics include self-amplifying, in-vivo self-replicating, and in-vitro dendritic cell non-replicating mRNA that combine the desirable immunological properties. These vaccines are usually injected into the body to trigger virus-detecting immune sensors and produce viral antigen protein cells, which aid in enhancing the immunity of the body by improving B- and T- cell responses.

Request Free Sample Report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample

Market Trends

The mRNA vaccines are more effective against pathogens, cost-efficient, and have enhanced immunogenicity and higher potency. As a result, leading players are focusing on the development of an mRNA-based vaccine for the coronavirus disease (COVID-19). The success of the vaccine for COVID-19 can potentially boost the market growth. Along with this, improvements in healthcare technologies, such as the development of lipid nanoparticle formulations for in-vivo systemic delivery of mRNA, is providing a positive impact on the industry. Besides this, due to the increasing prevalence of chronic ailments, such as diabetes, tuberculosis, cancer and cardiovascular diseases (CVDs), pharmaceutical companies are investing to combine multiple molecules into single therapeutic medicines. Moreover, extensive research and development (R&D) activities in biotechnology and rapid advancements that have facilitated multiplexing of mRNA for improved product profiles, are expected to create a positive outlook for the market in the coming years.

Ask Analyst and Browse Full Report with TOC & List of Figure: https://bit.ly/2VEjuxE

List of Key Companies Covered in this Market Report:

  • Argos Therapeutics Inc. (SCM Life Science and Genexine)

  • AstraZeneca /zigman2/quotes/200304487/composite AZN +2.59%

  • Bayer AG (otcmkts:BAYRY)

  • BioNTech AG /zigman2/quotes/214419716/composite BNTX -2.90%

  • Boehringer Ingelheim

  • CRISPR Therapeutics /zigman2/quotes/201181046/composite CRSP -0.27%

  • CureVac AG

  • eTheRNA Immunotherapies

  • Ethris GmbH

  • In-Cell-Art

  • Intellia Therapeutics Inc. /zigman2/quotes/207821052/composite NTLA +0.06%

  • Moderna Therapeutics /zigman2/quotes/205619834/composite MRNA -4.97%

  • Sangamo Therapeutics /zigman2/quotes/200395801/composite SGMO +3.50%

  • Tiba Biotech LLC

  • Translate Bio Inc.

The report has segmented the market on the basis of vaccine type, treatment type, vaccine manufacturing, application, end-user and geography.

Breakup by Vaccine Type:

  • Self-amplifying mRNA-based Vaccines

  • Conventional Non-Amplifying mRNA-Based Vaccines

  • Others

Breakup by Treatment Type:

  • Bioengineered Vaccine Based Treatment

  • Gene Therapy (Gene Silencing/Suppression)

  • Gene Transcription (Protein Generation)

  • Cell Therapy

  • Monoclonal Antibody Based Treatment

/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 66.21
+1.67 +2.59%
Volume: 7.17M
May 20, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
2.12%
Market Cap
$198.38 billion
Rev. per Employee
$500,529
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 163.00
-4.87 -2.90%
Volume: 1.20M
May 20, 2022 4:00p
P/E Ratio
2.79
Dividend Yield
0.94%
Market Cap
$40.80 billion
Rev. per Employee
$7.28M
loading...
/zigman2/quotes/201181046/composite
US : U.S.: Nasdaq
$ 56.34
-0.15 -0.27%
Volume: 1.34M
May 20, 2022 4:00p
P/E Ratio
15.64
Dividend Yield
N/A
Market Cap
$4.38 billion
Rev. per Employee
$1.94M
loading...
/zigman2/quotes/207821052/composite
US : U.S.: Nasdaq
$ 47.74
+0.03 +0.06%
Volume: 1.14M
May 20, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.62 billion
Rev. per Employee
$78,062
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 136.25
-7.13 -4.97%
Volume: 5.88M
May 20, 2022 4:00p
P/E Ratio
4.01
Dividend Yield
N/A
Market Cap
$57.03 billion
Rev. per Employee
$8.34M
loading...
/zigman2/quotes/200395801/composite
US : U.S.: Nasdaq
$ 4.14
+0.14 +3.50%
Volume: 3.97M
May 20, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$586.75 million
Rev. per Employee
$261,374
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.